14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $3.81 $4.85 Wednesday, 1st May 2024 NVAX stock ended at $4.67. This is 7.85% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 11.89% from a day low at $4.29 to a day high of $4.80.
90 days $3.53 $6.05
52 weeks $3.53 $11.36

Historical Novavax Inc prices

Date Open High Low Close Volume
Mar 10, 2016 $99.20 $101.20 $92.60 $95.00 221 845
Mar 09, 2016 $98.20 $99.60 $94.60 $98.20 179 080
Mar 08, 2016 $103.60 $103.80 $97.20 $97.60 313 195
Mar 07, 2016 $96.60 $106.60 $95.00 $102.80 337 920
Mar 04, 2016 $96.60 $99.80 $94.60 $97.20 302 175
Mar 03, 2016 $96.60 $97.40 $94.00 $95.80 391 125
Mar 02, 2016 $94.20 $97.80 $91.40 $96.40 482 680
Mar 01, 2016 $89.00 $96.40 $87.00 $94.00 879 245
Feb 29, 2016 $93.20 $96.00 $84.40 $87.20 606 250
Feb 26, 2016 $93.40 $95.00 $90.60 $94.20 273 600
Feb 25, 2016 $95.60 $97.80 $91.00 $91.80 298 855
Feb 24, 2016 $95.60 $96.80 $90.20 $95.80 301 850
Feb 23, 2016 $100.20 $102.00 $96.40 $96.60 191 685
Feb 22, 2016 $103.40 $104.40 $100.00 $100.60 245 040
Feb 19, 2016 $96.40 $102.60 $94.00 $101.20 432 500
Feb 18, 2016 $103.20 $104.00 $96.80 $97.20 389 890
Feb 17, 2016 $100.80 $102.80 $98.20 $101.40 403 415
Feb 16, 2016 $96.00 $102.00 $94.00 $98.00 414 450
Feb 12, 2016 $92.80 $93.60 $89.60 $92.20 310 500
Feb 11, 2016 $90.20 $93.20 $88.20 $90.60 526 525
Feb 10, 2016 $94.40 $100.20 $92.40 $93.20 407 285
Feb 09, 2016 $90.20 $97.00 $87.00 $92.40 430 745
Feb 08, 2016 $93.00 $95.20 $88.40 $93.00 728 150
Feb 05, 2016 $96.40 $97.20 $90.20 $96.20 879 540
Feb 04, 2016 $90.40 $99.00 $87.80 $97.60 543 180
Click to get the best stock tips daily for free!

About Novavax Inc

Novavax Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria... NVAX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT